Workflow
Protein Oral Delivery (POD™)
icon
搜索文档
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Globenewswire· 2025-04-28 21:00
Alpha Tau CEO Uzi Sofer commented, "We are delighted to welcome Oramed as a strategic partner and to leverage their extensive expertise in navigating diverse capital markets channels. This investment comes at the perfect time for Alpha Tau given the rapid expansion of our business activities, including four parallel trial approvals in the U.S., expansion into trials in multiple internal organs, and continued expansion of our manufacturing capacity and pre-commercial preparations. We look forward to a long a ...
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Prnewswire· 2025-04-28 21:00
战略投资与合作 - Oramed Pharmaceuticals通过注册直接发行成功收购Alpha Tau Medical约1410万股普通股 每股价格为2612美元 [1] - 双方签订为期三年的全面服务协议 Oramed将为Alpha Tau提供投资者与股东关系维护 业务战略指导以及资本市场专业知识 [2] - Oramed将任命两名董事进入Alpha Tau董事会 参与公司治理 [2] 技术协同与商业化 - 合作结合Oramed口服给药平台与Alpha Tau精准放射治疗技术 共同革新治疗递送方式 [1] - Alpha Tau正在推进四项美国临床试验 扩大多内脏器官试验范围 并持续提升制造能力与商业化准备 [3] - Alpha DaRT技术由特拉维夫大学专家开发 专注于实体肿瘤治疗 [5] 公司背景 - Oramed Pharmaceuticals是口服注射药物递送解决方案领域的技术先驱 拥有蛋白质口服递送(POD™)专利技术 [4] - Alpha Tau Medical成立于2016年 致力于Alpha DaRT®技术的研发与商业化 [5] 高管观点 - Oramed CEO认为此次合作是应用其资本市场专业能力支持突破性医疗技术的绝佳机会 对Alpha DaRT平台潜力充满信心 [3] - Alpha Tau CEO强调合作时机完美 可助力公司应对临床试验扩展 制造能力提升等业务快速发展需求 [3]